E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Tip 2 | |
E.1.1.1 | Medical condition in easily understood language | Type 2 diabetes | Dijabetes tipa 2 | |
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 | E.1.2 | Level | LLT | E.1.2 | Classification code | 10045242 | E.1.2 | Term | Type II diabetes mellitus | E.1.2 | System Organ Class | 100000004861 | |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial | To compare the effect of once-weekly dosing of two dose levels of subcutaneous semaglutide (0.5 mg and 1.0 mg) versus once-weekly dosing of two dose levels of subcutaneous dulaglutide (0.75 mg and 1.5 mg) on glycaemic control in subjects with type 2 diabetes on a background treatment with metformin. | Usporedba učinka supkutane primjene dviju doza semaglutida (0,5 mg i 1 mg) jednom tjedno u odnosu na supkutanu primjenu dviju doza dulaglutida (0,75 mg i 1,5 mg) jednom tjedno na kontrolu glikemije u ispitanika sa dijabetesom tipa 2 liječenih metforminom | |
E.2.2 | Secondary objectives of the trial | To compare the effect of once-weekly dosing of two dose levels of subcutaneous semaglutide (0.5 mg and 1.0 mg) versus once-weekly dosing of two dose levels of subcutaneous dulaglutide (0.75 mg and 1.5 mg) in subjects with type 2 diabetes on a background treatment with metformin with regards to: - Body weight control - Blood pressure - Patient reported outcomes - Safety and tolerability | Usporedba učinka supkutane primjene dviju doza semaglutida (0,5 mg i 1 mg) jednom tjedno u odnosu na supkutanu primjenu dviju doza dulaglutida (0,75 mg i 1,5 mg) jednom tjedno) u ispitanika sa dijabetesom tipa II liječenih metforminom na: - kontrolu tjelesne težine - krvni tlak -ishode prijavljene od strane ispitanika -sigurnost i podnošljivost | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria | - Male or female, age ≥ 18 years at the time of signing informed consent. - HbA1c 7.0 – 10.5% (53 – 91 mmol/mol) (both inclusive) - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal tolerated dose documented in the patient medical record) for 90 days prior to screening | - Muški ili ženski ispitanik/ca ≥18 godina u vrijeme potpisivanja informiranog pristanka - HbA1c 7.0 – 10.5% (53 – 91 mmol/mol) (obje vrijednosti uključive) - Ispitanici na stabilnom antidijabetičkom liječenju metforminom (minimalno 1500 mg/dan ili najviša podnošljiva doza dokumentirana u ispitanikovim medicinskim zapisima) barem 90 dana prije probira | |
E.4 | Principal exclusion criteria | - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). - Any condition, which in the investigator’s opinion might jeopardise subject’s safety or compliance with the protocol - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term insulin treatment for acute illness for a total of ≤14 days - History of pancreatitis (acute or chronic) - Screening calcitonin ≥50 ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma - Renal impairment defined as eGFR < 60 mL/min/1.73 m^2 as per CKD-EPI - Subjects presently classified as being in New York Heart Association Class IV - Planned coronary, carotid or peripheral artery revascularisation on the day of screening - Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days or on a frequent basis) known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, corticosteroids) | - Žena koja je trudna, doji ili planira zatrudnjeti ili je u reproduktivnoj dobi a ne kortisti odgovarajuću kontraceptivnu metodu (hormonski kontraceptivi, sterilizacija, intrauterini uložak, metode barijere – kondomi ili dijafragma u kombinaciji sa spermicidnim sredstvima /krema, pjene, gelovi/ i, ako je primjenjivo, suzdržavanje od odnosa) -Bilo koja stanja koja po mišljenju ispitivača mogu ugroziti sigurnost ispitanika ili pridržavanje plana ispitivanja -Liječenje bilo kojim lijekom za indikaciju dijebetesa ili pretilosti osim navedenih u uključnim kriterijima u razdoblju od 90 dana prije probira. Iznimka je kratkotrajno liječenje inzulinom za akutne bolesti u trajanju ≤14 dana - Povijest pankreatitisa (akutnog ili kroničnog) - Kalcitonin na probiru ≥50 ng/L | |
E.5 End points |
E.5.1 | Primary end point(s) | Change in HbA1c | Promjena u HbA1c | |
E.5.1.1 | Timepoint(s) of evaluation of this end point | From baseline to week 40 | Od početnih vrijednosti do 40. tjedna | |
E.5.2 | Secondary end point(s) | Change in 1. Body weight (kg) 2. Fasting plasma glucose 3. Systolic and diastolic blood pressure 4. Overall scores for patient reported outcomes: Diabetes Treatment Satisfaction Questionnaire 5. Subjects who achieve (yes/no) HbA1c ≤6.5% (48 mmol/mol) American Association of Clinical Endocrinologists target | Promjena u 1. Tjelesnoj težini (kg) 2. Vrijednosti glukoze u plazmi natašte 3. Sistoličkom i dijastoličkom krvnom tlaku 4. Ukupni rezultat za ishode prijavljene od strane ispitanika: Upitnici o zadovoljstvu liječenja dijabetesa 5. Ispitanici koji postignu (da/ne) HbA1c ≤6.5% (48 mmol/mol), što je cilj Američkog društva za kliničku endokrinologiju | |
E.5.2.1 | Timepoint(s) of evaluation of this end point | 1-4. From baseline to week 40 5. After 40 weeks treatment | 1-4. Od početnih vrijednosti do 40. tjedna 5. Nakon 40 tjedana liječenja | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 | The trial involves single site in the Member State concerned | No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 85 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned | Canada | European Union | Hong Kong | India | United States | |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 | Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial | |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 18 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 18 |